Drug Trial Radar · NCT04093596
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Sep 23, 2019
Primary completion
Jan 27, 2025
Study completion Jan 27, 2025
Sponsor
- Lead sponsor
- Allogene TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and immunogenicity of ALLO-715 with or without Nirogacestat in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen of ALLO-647 in combination with fludarabine and/or cyclophosphamide, or ALLO-647 alone.
Conditions
- Relapsed/Refractory Multiple Myeloma
Interventions
ALLO-715Genetic
ALLO-715 is an allogeneic CAR T cell therapy targeting BCMA
ALLO-647Biological
ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
FludarabineDrug
Chemotherapy for lymphodepletion
CyclophosphamideDrug
Chemotherapy for lymphodepletion
NirogacestatDrug
a small molecule, selective, reversible, noncompetitive inhibitor of γsecretase (GSI) that increases BCMA target density on the surface of multiple myeloma cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-715Time frame: 28 Days
- To assess the overall safety profile and tolerability of ALLO-647 in combination with Fludarabine and/or cyclophosphamide or ALLO-647 alone, prior to ALLO-715 to confirm the dose of ALLO-647.Time frame: 33 days
- To assess the overall safety profile and tolerability of nirogacestat given concomitantly with ALLO-715 following lymphodepletion with Flu/ Cy/ ALLO-647.Time frame: 28 days
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
City of Hope
Duarte, California
Stanford Cancer Institute
Palo Alto, California
Sarah Cannon/Colorado Blood Cancer Institute
Denver, Colorado
Mayo Clinic
Rochester, Minnesota
Memorial Sloan Kettering Cancer Center
New York, New York
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
St. David's South Austin Medical Center
Austin, Texas
Texas Transplant Institute
San Antonio, Texas
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.